drugset
drugset / Trial / NCT06148025

Antibiotics and Vaccine Immune Responses Study

NCT06148025 ↗

Phase 4 Recruiting 348 enrolled South Australian Health and Medical Research Institute Centenary Institute · collabFlinders University · collabRoyal Adelaide Hospital · collabTelethon Kids Institute · collabUniversity of Sydney · collab
RandomizedParallel-groupDouble-blindBasic science

Summary

The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination. The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system?

Timeline

Start
2023-11-23
Primary completion
2027-10-01
Completion
2028-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject BCG vaccine Vaccine 0.1 ml Other
Subject Neomycin Unknown 1000 mg Oral
Subject Vancomycin Other / unclassified 500 mg Oral
Subject Yellow Fever Vaccine Vaccine 0.5 ml Subcutaneous
Background Loperamide Small molecule 2 mg —
Background Metoclopramide Small molecule 10 mg —

Indications

No indication recorded.